The generation of Eμ-Myc/dCas9a-SAMKI/+/sgBcl-2 lymphoma cell lines, that are highly sensitive to venetoclax and CRISPRa enabled, provided a model system in which whole genome CRISPR activation screens could be carried out to identify genes that confer drug resistance when upregulated. The gene discussed is MYC; the disease is lymphoma.